Treatment with 5-HT1AR antagonists (e.g., NAD-299 and WAY-100635) has been shown to reduce amyloid plaque deposition, increase levels of hippocampal BDNF, alleviate neuroinflammation and oxidative stress, and improve cognitive deficits in individual animal models of AD (Afshar et al., 2018, 2019; Wang et al., 2020; Table 3). The gene discussed is BDNF; the disease is Alzheimer disease.